


GANCICLOVIR FOR INJECTION, USP



To most, “generics” means bland, ordinary, and uninteresting. To us, it means the opportunity to be remarkable.

PRODUCT DETAILS

- Strength: 500 mg per vial
- Fill Volume: Lyophilized Powder in a 10 mL vial
- Therapeutic Class: Antiviral
- Closure does not contain any natural rubber or latex
- Preservative free

Saleable Unit:

500 mg | Box of 25 vials |
70436-089-55

See reverse side for important safety information.

To place an order or learn more, call **888-447-0095 (Toll Free)** or email sales@slaterunpharma.com 6am - 7pm CST (Monday - Friday)

Available through your wholesaler:

NDC: 70436-089-55
Cardinal Health: 5520945
McKesson: 3935939
Amerisource: 10213365

— MAKING —
GENERICS
REMARKABLE

IMPORTANT SAFETY INFORMATION FOR:
GANCICLOVIR FOR INJECTION, USP

WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS

Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir.

Impairment of Fertility: Based on animal data and limited human data, ganciclovir for injection may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.

Fetal Toxicity: Based on animal data, ganciclovir for injection has the potential to cause birth defects in humans.

Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir for injection has the potential to cause cancer in humans.

Ganciclovir for injection is contraindicated in patients who have experienced a clinically significant hypersensitivity reaction (e.g., anaphylaxis) to ganciclovir, valganciclovir, or any component of the formulation.

Ganciclovir for injection should be used with caution in patients with renal impairment because the half-life and plasma/serum concentration of ganciclovir will be increased due to reduced renal clearance. If renal function is impaired, dosage adjustments are recommended.

The most common adverse reactions and laboratory abnormalities reported in at least 20% of patients were pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, decreased appetite, dyspnea, abdominal pain, sepsis, hyperhidrosis, and blood creatinine increased.

Please see the package insert for Ganciclovir for Injection for full prescribing information.